Total Payments
$116,445
2024 Payments
$24,821
Companies
52
Transactions
1,333
Medicare Patients
4,952
Medicare Billing
$9.8M
Payment Breakdown by Category
Other$82,675 (71.0%)
Food & Beverage$22,840 (19.6%)
Consulting$7,460 (6.4%)
Travel$3,285 (2.8%)
Education$185.16 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $82,675 | 51 | 71.0% |
| Food and Beverage | $22,840 | 1,227 | 19.6% |
| Consulting Fee | $7,460 | 14 | 6.4% |
| Travel and Lodging | $3,285 | 29 | 2.8% |
| Education | $185.16 | 12 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $93,558 | 270 | $0 (2024) |
| Ironwood Pharmaceuticals, Inc | $7,311 | 26 | $0 (2018) |
| Amgen Inc. | $2,754 | 168 | $0 (2024) |
| Janssen Biotech, Inc. | $1,953 | 157 | $0 (2024) |
| PFIZER INC. | $1,340 | 124 | $0 (2024) |
| UCB, Inc. | $1,092 | 69 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,039 | 60 | $0 (2024) |
| Lilly USA, LLC | $942.51 | 71 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $793.36 | 59 | $0 (2024) |
| Genentech USA, Inc. | $696.84 | 51 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,821 | 209 | ABBVIE INC. ($21,973) |
| 2023 | $20,891 | 194 | AbbVie Inc. ($18,169) |
| 2022 | $19,285 | 189 | ABBVIE INC. ($17,203) |
| 2021 | $5,661 | 41 | AbbVie Inc. ($5,285) |
| 2020 | $9,783 | 43 | AbbVie Inc. ($9,343) |
| 2019 | $13,773 | 213 | AbbVie, Inc. ($11,537) |
| 2018 | $15,945 | 230 | Ironwood Pharmaceuticals, Inc ($7,242) |
| 2017 | $6,286 | 214 | AbbVie, Inc. ($3,885) |
All Payment Transactions
1,333 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $0.92 | General |
| Category: Immunology | ||||||
| 12/18/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Analgesic | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $6.71 | General |
| Category: Immunology | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/16/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $10.33 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/13/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: RESPIRATORY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $29.76 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Immunology | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $95.98 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Immunology | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/03/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $8.72 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $2.69 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $31.11 | General |
| Category: Dermatology | ||||||
| 11/25/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $8.23 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/22/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,081 | 186,292 | $8.6M | $2.1M |
| 2022 | 20 | 1,223 | 185,087 | $8.5M | $2.2M |
| 2021 | 18 | 1,309 | 138,001 | $7.8M | $2.3M |
| 2020 | 23 | 1,339 | 156,809 | $7.2M | $3.1M |
Total Patients
4,952
Total Services
666,189
Medicare Billing
$9.8M
Procedure Codes
81
All Medicare Procedures & Services
81 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 41 | 23,425 | $2.6M | $787,937 | 30.6% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 80 | 50,850 | $2.5M | $523,946 | 20.6% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 27 | 61,200 | $1.2M | $239,139 | 19.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 34 | 7,820 | $1.1M | $204,416 | 17.9% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 14 | 37,880 | $568,200 | $177,392 | 31.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 149 | 579 | $154,014 | $55,476 | 36.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 31 | 2,940 | $147,000 | $53,749 | 36.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 268 | 471 | $99,381 | $40,579 | 40.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 47 | 227 | $34,277 | $12,179 | 35.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 99 | 236 | $32,096 | $11,153 | 34.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 70 | $10,080 | $4,058 | 40.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 42 | 173 | $10,034 | $3,603 | 35.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $10,846 | $3,535 | 32.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 16 | $4,528 | $2,093 | 46.2% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 22 | 44 | $9,680 | $1,708 | 17.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 52 | 149 | $4,768 | $1,572 | 33.0% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 20 | 24 | $2,808 | $1,115 | 39.7% |
| 77077 | X-ray of joints, multiple | Office | 2023 | 15 | 27 | $1,125 | $357.80 | 31.8% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 19 | 22 | $550.00 | $205.13 | 37.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 17 | 105 | $1,680 | $87.47 | 5.2% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 45 | 22,050 | $2.4M | $762,932 | 31.5% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 86 | 50,200 | $2.5M | $583,246 | 23.2% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 37 | 62,000 | $1.2M | $278,716 | 22.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 40 | 8,670 | $1.3M | $246,705 | 19.5% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2022 | 14 | 37,240 | $558,600 | $172,607 | 30.9% |
About Dr. James Beekman, MD
Dr. James Beekman, MD is a Internal Medicine healthcare provider based in Greensboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043221013.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Beekman, MD has received a total of $116,445 in payments from pharmaceutical and medical device companies, with $24,821 received in 2024. These payments were reported across 1,333 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($82,675).
As a Medicare-enrolled provider, Beekman has provided services to 4,952 Medicare beneficiaries, totaling 666,189 services with total Medicare billing of $9.8M. Data is available for 4 years (2020–2023), covering 81 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Greensboro, NC
- Active Since 08/11/2006
- Last Updated 08/03/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1043221013
Products in Payments
- RINVOQ (Biological) $40,429
- SKYRIZI (Biological) $22,202
- Humira (Biological) $9,927
- Rinvoq (Biological) $7,982
- DUZALLO (Drug) $7,268
- HUMIRA (Biological) $5,890
- RINVOQ (Drug) $3,454
- Enbrel (Biological) $1,873
- XELJANZ (Drug) $1,117
- Cimzia (Drug) $1,013
- SIMPONI ARIA (Biological) $872.40
- ORENCIA (Biological) $811.97
- TALTZ (Drug) $770.77
- COSENTYX (Biological) $654.05
- BENLYSTA (Biological) $619.35
- TREMFYA (Drug) $604.37
- Rituxan (Biological) $538.78
- STELARA (Biological) $406.39
- COSENTYX (Drug) $384.79
- EVENITY (Biological) $345.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Greensboro
Dr. Daniel Bensimhon, Md, MD
Internal Medicine — Payments: $2.3M
Internal Medicine $2.3M
Dr. Michael Wert, M.d, M.D
Internal Medicine — Payments: $439,242
Internal Medicine $439,242
Mark Russo, Md, MD
Internal Medicine — Payments: $318,372
Internal Medicine $318,372
Julian Hutchins, Md, MD
Internal Medicine — Payments: $222,266
Internal Medicine $222,266
Walter Pharr, M.d, M.D
Internal Medicine — Payments: $53,823
Internal Medicine $53,823
Murali Ramaswamy, Md Faafp, MD FAAFP
Internal Medicine — Payments: $45,364
Internal Medicine $45,364